COVID-19 Patient Cohort: Retinal Damage in Non-invasive Retinal Imaging (OCTA)

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04881253

Enrollment

Registered

2021-05-11

Start date

2021-11-05

Completion date

2023-01-17

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Retina Injury

Keywords

OCT-A, OCT

Brief summary

The objective of this research is to build a collection of non-invasive retinal imaging (OCT and OCTA) in order to investigate the incidence and impact of retinal damage in patients who have or have had COVID-19.

Detailed description

This monocentric study is aimed at 3 types of patients: * Those who have been hospitalized for Covid-19 during the epidemic * Newly infected and diagnosed patients Covid-19 * Those with paucisymptomatic Covid-19 who did not require hospitalisation At the patient's inclusion, an ophthalmologic assessment will be performed including : * visual acuity, * SD-OCT + multicolor, * OCT-A, * color retinography, Fundus examination, optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) in all COVID-19 patients may detect retinal lesions. In addition, if a correlation is demonstrated between clinical and paraclinical parameters and between disease severity and retinal vascular damage in non-invasive imaging (OCT and OCTA), this would allow a better understanding of the pathophysiology of the disease, as well as factors that may influence disease severity and the mechanisms potentially responsible for the observed disorders.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years old * Diagnosis of COVID-19 proven on RT-PCR, antigenic test or chest CT scan * Affiliation to the general social security system * A consent signed by the patient

Exclusion criteria

\- Refusal of patient participation

Design outcomes

Primary

Measure	Time frame	Description
Retinal damage at inclusion after Covid-19 infection	Up to one week after inclusion	Comparison of retinal damage in patients with patients with severe forms of Covid-19 versus patients with mild forms of the disease

Secondary

Measure	Time frame	Description
Change of retinal vascular density at inclusion after Covid-19 infection	Up to one week after inclusion	Comparison of retinal damage in patients with severe forms of Covid-19 versus patients with mild forms of the disease
Impact of retinal vascular density changes on visual acuity at inclusion	Up to one week after inclusion	Severity and impact of retinal damage
Presence of Retinal toxicity (atrophy) on multimodal retinal imagery	Up to one week after inclusion	Correlation between the presence of changes in multimodal imaging (fundus autofluorescence, multicolor and OCTA) and the associated antiviral treatment for Covid-19.

Countries

France

Outcome results